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A B S T R A C T
Photoacoustic imaging (PAI) provides information on haemoglobin levels and blood oxygenation (sO2). To fa-
cilitate assessment of the variability in sO2 and haemoglobin in tumours, for example in response to therapies,
the baseline variability of these parameters was evaluated in subcutaneous head and neck tumours in mice, using
a PAI system (MSOTinVision-256TF). Tumours of anaesthetized animals (midazolam-fentanyl-medetomidine)
were imaged for 75min, in varying positions, and repeatedly over 6 days. An increasing linear trend for average
tumoural haemoglobin and blood sO2 was observed, when imaging over 75min. There were no significant
differences in these temporal trends, when repositioning tumours. A negative correlation was found between the
percent decrease in blood sO2 over 6 days and tumour growth rate. This paper shows the potential of PAI to
provide baseline data for assessing the significance of intra- and inter-tumoural variations that may eventually
have value for predicting and/or monitoring cancer treatment response.
1. Introduction
The immature, tortuous and hyperpermeable vascular network
often found in tumours may not provide sufficient nutrients and oxygen
for rapid and uncontrolled cell proliferation, which can result in regions
of tumour cell hypoxia, i.e. low oxygen concentration in the vicinity of
tumour cells [1]. Temporal fluctuations in the hypoxic state also occur
[2], on a time-scale of minutes or hours when they result from an efflux
of red blood cells, or days when they are due to vascular network re-
modelling and angiogenesis [3].
Hypoxia is associated with increased resistance to chemo- and
radiotherapy (as extensively reviewed by Rockwell et al. [4]), two
commonly used clinical cancer treatments. Assessing the spatial and
temporal variation in hypoxia levels could be predictive of a cancer
therapy response and may therefore have a crucial role in treatment
planning and adaptation [5,6]. Conventionally, oxygen needle elec-
trodes have been used to assess hypoxia in patients, by directly mea-
suring tissue partial oxygen pressure (pO2) [7]. However, needle elec-
trodes are invasive and provide only a local value, which is not
representative of the whole tumour. Techniques which use conven-
tional non-invasive imaging have been developed to attempt to infer,
not only the oxygenation levels, but also the spatial distribution of
hypoxia. Several Positron Emission Tomography (PET) radiotracers are
available [8–10], providing a noninvasive alternative, albeit with a
relatively poor spatial resolution and high cost.
Unfortunately, the use of radioactive isotopes is also ill-suited to
longitudinal studies due to radiation dose accumulation. Blood oxyge-
nation level dependent (BOLD)-magnetic resonance imaging (MRI) [11]
enables the measurement of relative blood oxygen saturation (sO2)
increase during carbogen challenge compared to air-breathing. It has
been shown that these measurements are in good spatial agreement
with tissue pO2 measurements [12–14] and histological markers of
hypoxia [15,16]. BOLD-MRI, however, has poor specificity for hypoxia,
and does not provide absolute sO2.
Recently, the use of combined ultrasound (US) and optical imaging
techniques, such as photoacoustic imaging (PAI), has been proposed as
a method of non-invasively mapping blood sO2 [17–20]. PAI can
identify the unique spectral signatures of deoxy- (Hb) and oxyhae-
moglobin (HbO2) [17]. The quantification of the local levels of each
chromophore further allows mapping of blood sO2 distribution in the
tissue, defined as the ratio of HbO2 to the total amount of haemoglobin
(HbT, the sum of HbO2 and Hb) [21].
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PAI has been used for hypoxia mapping pre-clinically, in sub-
cutaneous [15,18,21–26] and brain tumours [27], showing good
agreement with pimonidazole staining [18,22], an exogenous hypoxia
marker [15], and gold nanorods [28], and imaging modalities, such as
bioluminescence [20], high resolution and dynamic contrast enhanced
US [21,23] and BOLD-MRI [24,25].
PAI provides a powerful tool for quantifying tumour blood sO2 and
has the potential of being used in clinic to predict and monitor treat-
ment response involving changes in tumour vasculature. A potential
limitation is that variability resulting from the measurement technique,
or the intrinsic biological variability, may obscure changes resulting
from a treatment. Primary sources of variability could be technical
(system hardware, positioning of the tumour with respect to imaging
transducer, data processing) and/or biological (effect of anaesthesia,
tumour growth). It is known that anaesthetic agents significantly alter
haemodynamic parameters. For example in mice, isoflurane, urethane,
pentobarbital sodium, or ketamine-xylazine anaesthesia are known to
cause substantial effects on haemodynamic parameters [29]. Such
variability needs to be considered when interpreting changes in tumour
vasculature in response to therapies. Joseph et al. [30] performed a
technical validation study of a PAI tomography system (MSOT-inVision
256-TF, iThera Medical), demonstrating both reproducibility and re-
peatability of the measurements in phantoms and in vivo. They showed
that the position of the test object with respect to the transducer had the
greatest impact on signal repeatability. Joseph et al. also monitored the
influence of inhaled isoflurane on sO2 measurements in kidney and
spleen. This present paper aims to characterise the biological variability
of photoacoustic imaging measurements of Hb, HbO2, HbT and sO2 in a
subcutaneous head and neck tumour model, commonly hypoxic, using
the same commercial PAI tomography system. Short-term intrinsic
biological variability, for a period of 75min, was tested to investigate
the effect of anaesthesia on tumoural sO2 and HbT. The tumour posi-
tions (with respect to the imaging transducer) were also altered to
understand the impact on signal variability. Long-term variability in the
parameters of growing tumours was assessed over a period of 6 days.
Our results demonstrated the importance of assessing such tumoural
baseline measurements prior to performing studies involving prediction
and monitoring of treatment response, involving a change in sO2 and
HbT.
2. Methods
2.1. Tumour model and growth rates
All research was conducted under the Guidelines of Animal Welfare
provided by the UK Home Office with approval from the local animal
welfare and ethics board and under Helsinki Declaration of 1975.
The human head and neck squamous cell tumour model, CALR, used
for this study is a noncommercially available cancer cell line developed
at the Institute of Cancer Research [31].
Half a million cells were injected subcutaneously into the right flank
of 6 week old female FOXnun1 mice (∼25 g). Animals were monitored
for the development of a mass. Once palpable, tumour dimensions were
measured every 2 or 3 days, in 3 orthogonal directions (length (l),
width (w) and height (h)), using Vernier calipers. Tumour volume (V)
was calculated assuming an ellipsoidal shape, as commonly used for
subcutaneous tumours, according to Eq. (1).
= × × ×V l w h1
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The volume error (Verror), for each individual tumour, was estimated
from the derivative of an ellipsoidal volume, assuming a measurement
error (Em) of 0.5mm in each direction, using Eq. (2).
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Tumour dimensions are therefore presented as mean volume plus
standard deviation of the estimate, based only on the accuracy of the
three orthogonal dimension measurements, ignoring any deviation in
shape from an ellipsoid.
Tumour growth curves were fitted to the Exponential-Linear Model
for calculating tumour growth rates [32]. Two rates were calculated: α0
is the growth rate during the exponential phase, and α1 is the growth
rate in the linear phase. For details of these calculations, see Supple-
mentary Methods.
2.2. Photoacoustic imaging data acquisition and reconstruction
Mice were imaged using a commercially available, real time, mul-
tispectral optoacoustic tomographic (MSOT) device, inVision 256-TF
small animal scanner (iThera Medical GmbH, Munich, Germany) [29].
The system has a tunable optical parametric oscillator pumped by a Q-
switched Nd:YAG near-infrared laser. A 256 element, toroidally fo-
cused, ultrasound imaging transducer (4 cm radius) with a centre fre-
quency of 5MHz (60% bandwidth) was used to acquire the acoustic
signal, resulting from the optical tissue excitation. These elements cover
an angle of 270° around the tumour to create a cross-sectional image.
Tumours were first imaged (defined as Day1) when they reached a
volume of approximately 200 mm3. Anaesthesia was induced using an
intraperitoneal injection of midazolam:fentanyl:medetomidine
(5.0:0.05:0.5mg kg−1). This anaesthetic combination is known to
provide long anaesthesia times (∼60min) [33]. It is suitable for studies
involving protocols which could potentially cause pain (e.g. therapies
involving tissue heating) or where mice need to be re-anaesthetised
multiple times over a short period (e.g. multimodality imaging, ima-
ging-therapy studies), as will be performed by us as a part future work.
Mice were placed horizontally in a holder encased in a thin (17 μm)
polyvinyl chloride (PVC) film (see Supplementary Fig. S1), with their
tumour facing vertically downwards, i.e. directly in the direction of the
laser beam, and acoustically coupled to the membrane using ultrasound
imaging gel. In order to provide acoustic coupling to the MSOT, the
animal holder was completely submerged in a tank filled with 34 °C
distilled water. During immersion, medical air (21% oxygen) and/or
100%-oxygen were supplied continuously to the mouse via tubing, in
order to avoid asphyxiation. Imaging started approximately 5min after
placing the holder in the water tank, in order to allow the animal’s body
temperature to equilibrate with the water’s temperature.
For acquiring the photoacoustic data, a volume of interest (VOI),
containing the whole tumour was selected to avoid a large dataset.
Transverse (medial-lateral direction) imaging slices were acquired at
1mm intervals in the cranial-caudal direction. The optical imaging
wavelengths used were: 700, 715, 730, 750, 760, 800, 850, and
900 nm. This wavelength range maximises the differences in Hb and
HbO2 signals. Ten signal averages per wavelength were obtained for
each imaging slice.
Photoacoustic images were reconstructed using a model-based in-
version algorithm [34] which was implemented in the viewMSOT
software (v3.8) provided by iThera Medical.
Spectral unmixing was used to calculate the contribution of each
chromophore, HbO2 and Hb, in blood, in order to calculate the sO2.
This is done on a pixel-by-pixel basis, using a linear regression algo-
rithm [35]. Pixels which indicated regions where the total amount of
haemoglobin is so low, or sources of noise so high, that adequate
confidence in spectral recognition could not be achieved, or where the
reconstruction method produced pixels with negative Hb and HbO2
values, were set to a zero value. The software subsequently allows
calculation of the mean HbO2 and Hb signals (which includes the zero
value pixels) in a user defined region of interest (ROI) which could be
drawn onto the greyscale anatomical image (Fig. 1A). These mean Hb
and HbO2 values are added together to calculate the mean total hae-
moglobin per ROI. For any ROI the mean oxygen saturation was cal-
culated using Eq. 3.
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= +mean sO mean HbOmean HbO mean Hb2 22 (3)
All the parameters are unitless quantities, described in arbitrary
units (A.U.), because the software does not use light fluence correction
and the system response in calculations, as would be necessary to
quantify the concentration (in mmol/L or mg/L) of each chromophore.
The viewMSOT software also allows mapping of the spatial distribution
of sO2 calculated on a pixel-by-pixel basis, obtaining an ‘oxymap’
(Fig. 1B). This was not used for calculating the mean sO2 values in ROIs
because it was observed that the software did not account for the zero
value pixels when calculating the mean values of sO2 in a region of
interest. These pixels are discarded from the analysis. For each 3D
imaging scan, 3 slices were always chosen for the analysis of Hb, HbO2,
HbT and sO2.
2.3. Imaging studies
Three separate imaging studies were performed.
The first was a short-term MSOT study designed to investigate any
potential effects of anaesthesia on HbT and blood sO2. A 3D whole
tumour dataset was acquired every 5min for 75min, after allowing
5min for the tumour to reach thermal equilibrium with the imaging
system. Only air-breathing imaging was acquired, in order to maximise
the rate (and number) of datasets that could be acquired. Measurements
were acquired in 4 animals when their tumours reached a target volume
of 200 mm3.
The PAI optical fluence is depth-dependent, and hence the position
of tissue of interest with respect to the imaging transducer can affect the
PAI measurements, as this can alter the amount of near-infrared light
attenuated by overlying tissue, as well as the field intensity incident on
that position. In order to study how re-positioning the animal affects
measurements of blood haemoglobin and blood sO2, a second short
term study was performed, 24 h after the first study. The same 4 ani-
mals were anaesthetised once and imaged in three consecutive sessions
after being dismounted from the imaging system between each session.
In addition, the tumour was placed at a slightly different position re-
lative to the transducer each time. Whole tumour 3D datasets were
acquired first under air breathing conditions which took approximately
2min, and then under 100% oxygen breathing, after allowing 2min for
the oxygen to reach the tumour, for the same VOI, under hyperoxic
conditions [25]. Oxygen breathing can be used as a contrast agent for
PAI, enhancing tumour and spatial differences when vascularity is im-
aged using sO2 [36]. Approximately 4min were needed to remove the
animal from the holder, reposition it and replace it.
For both short-term studies, a linear regression model was applied
to calculate an estimate of the average change in signal over time, as
well as the goodness of fit between the imaging data and the model.
This was obtained using the curve fitting toolbox (version 3.5.3)
available in MATLAB R2016a software. To investigate the suitability of
the linear model for these studies, three parameters were calculated:
goodness of fit (R2) that indicates how much of the variability of the
parameter (Hb, HbO2, HbT and sO2) is time-dependent; p-value of the
model which shows if the slope is significantly different from 0 (if p-
value< 0.05); and the Sum of Squared Errors (SSE) of the prediction
model that indicates the suitability of the linear model for explaining
the variability behaviour of the data (the closer SSE is to 0, the better
the linear fitting). The temporal variations of both the 75min and the
re-positioning study were also compared by calculating if there were
statistical differences in signal change between studies, using an ana-
lysis of covariance (software: GraphPad Prism 7).
The third, a long-term study, was designed to image tumours se-
quentially during a period of growth. When tumours (n=10) reached a
volume of approximately 200 mm3, animals were imaged on 3 con-
secutive days (‘Day 1, 2 or 3′). This volume was chosen as being suitable
for future studies of cancer treatment e.g. using radiotherapy. Tumours
were also imaged on day 6 in order to evaluate changes in haemoglobin
and blood sO2 during tumour growth. For this study, animals were
imaged under air- and oxygen-breathing conditions.
For short- and long-term studies, three slices in each tumour, se-
parated by 1mm, were chosen for analysis, a central slice and the ad-
jacent slice on either side. The mean haemoglobin and blood sO2 values
were obtained by averaging over the three whole-tumour ROIs to
provide the tumour ROI-averaged Hb, HbO2, HbT and sO2. For each
animal, the average percentage of black pixels in the three central tu-
mour slices was also calculated in order to evaluate the signal lost in
each ROI. For the repositioning and long term studies, ΔsO2, i.e., the
difference in blood sO2 between air- and oxygen-breathing was also
calculated, as it has been shown as a useful parameter in other PAI
published literature [25,36].
2.4. Statistical analysis
The slice-, intra-tumour and inter-tumour coefficients of variation
(CoVs), i.e. the ratio of standard deviation to mean, were calculated for
Hb, HbO2, HbT and sO2 in all PAI studies. Intra- and inter-tumour CoVs
of ΔsO2 were also calculated for the repositioning and 6-day studies.
The first indicates how much variation to expect between the 3 ROIs
chosen for the analysis of the PAI parameters; the second the variation
of the measurements for each animal and the third the variation be-
tween animals.
A paired student t-test was used to assess the level/degree of
Fig. 1. A: Greyscale photoacoustic image ob-
tained from optical excitation at a single wa-
velength (800 nm). The yellow polygon is the
ROI used to delineate the tumour. B: Shows an
‘oxymap’ overlaid on the tumour. The
‘oxymap’ colour scale on the right represents
the blood sO2 calculated by the MSOT software
on a pixel-by-pixel basis. Blue represents
sO2<0.5 A.U (white), while red is
sO2>0.5 A.U. Black pixels within the ROI
show where haemoglobin signals are below the
noise threshold.
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significance of differences in the mean Hb, HbO2, HbT and sO2 of CALR
tumours during the long-term variability studies, on imaging days 1, 2,
3 and 6, using R software.
3. Results
3.1. Short term PAI variability study
3.1.1. Variation in time: 75 min
For the first short-term study, aimed at investigating the effect of
anaesthesia over 75min in the photoacoustic imaging measurements,
four animals were imaged. Fig. 2 shows the short term variation in the
ROI-averaged percentage of black pixels and average Hb, HbO2, HbT
and sO2, over the three tumour slices per animal. A trend of a decrease
in the percentage of black pixels (i.e. those with undetectable levels of
haemoglobin), is observed for animals 1, 2 and 4 after the initial 10min
of imaging, after an initial increase between 5 and 10min. Animal 3 has
a more constant percentage of black pixels compared to the remaining 3
animals, over the whole imaging time. An increase in Hb and HbO2
(and therefore HbT), and sO2 over the whole time period was observed
for all tumours, except for the sO2 values measured for animal 3.
Fig. 3 shows an example of the oxygenation maps obtained for this
study. A radial sO2 gradient, but over time, more white and pink re-
gions (blood sO2≥0.5) extend towards the middle of the tumour, and
the margins attached to the body shift from dark blue to light blue,
consistent with the indication of increased blood sO2.
The different change rates are shown in Table 1. This summarises
the ROI-averaged rate of change of Hb, HbO2, HbT, sO2 and percentage
of black pixels (%BP), as well as the goodness of fit (R2) and the sum of
squares of error (SSE) of the linear regression used to calculate these
rates of signal change. Animals 1 and 2 had a faster increase in Hb (and
HbO2 than animals 3 and 4. This was reflected in the rate of HbT over
75min. While for animals 1 and 2, the increase in HbT was> 0.027
min−1, for animals 3 and 4, this rate was<0.015 min−1. Animals 1
and 2 also had a faster decrease in %BP (-0.278min−1 and
-0.146min−1, respectively) compared to animals 3 and 4
Fig. 2. ROI-averaged percentage of black pixels, and Hb, HbO2, HbT and sO2 signals, for CALR tumours (n=4) imaged over 75min, during air-breathing. Error bars
represent the standard deviation over 3 adjacent central tumour slices (ROIs), 1 mm apart. Solid lines represent a linear regression fitted to the data.
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(-0.0284min−1 and -0.081min−1, respectively).
Table 1 also shows the increase in blood sO2. Animals 1, 2 and 4,
had similar increases in blood sO2 (range: 0.0027-0.0031), but for an-
imal 3, the blood sO2 rate of change was negligible, 0.00025 (3.148e-
05, 0.00047), with R2 = 0.267. This is a consequence of a similar in-
crease in Hb (0.0079min−1) and HbO2 (0.0071min−1).
The average slice-CoV, intra- and inter-tumour CoVs in ROI-aver-
aged Hb, HbO2, HbT and sO2, over the 75min acquisition for each
animal, are summarised in Table S1. Overall, the intra-tumour CoV was
higher for the haemoglobin components (Hb: 22.5±6.0%; HbO2:
40.2±13.9%; HbT: 22.9±9.2%) than for sO2 (16.0±8.4%). The
slice-CoV, indicative of the variation of photoacoustic imaging para-
meters, in the 3 ROIs chosen for each tumour, was lowest for all the
parameters (< 13.9 ± 7.4%) compared to the intra-tumour CoV.
The inter-tumour CoV calculated for this study was 20.9 ± 3.1%
for Hb, 46.4 ± 12.4% for HbO2, 28.6 ± 2.3% for HbT and
21.8 ± 10.9% for sO2. The largest variation was consistently measured
for HbO2. These results show that, for the short-term longitudinal study,
inter- and intra-tumour CoV were similar, showing a high variability is
expected for each animal when imaged over 75min.
3.1.2. Re-positioning study
The results for the study on the effect of repositioning 4 animals
three times in close succession in the photoacoustic system are shown in
Figs. 4 and 5. The trends for air- and oxygen-breathing were similar, so
the results for air-breathing are shown here and the results for oxygen-
breathing are in the Supplementary material (Fig. S2 and Tables S2–3).
The ‘oxymap’ of the central tumour slice for each mounting position for
each CALR tumour is shown overlain on greyscale anatomical images in
Fig. 4. The images suggest a blood sO2 gradient radially into the tu-
mour, ie, the margin below the skin tends to have higher blood sO2,
compared to centre and margin attached to the mouse flank. The shapes
and sizes of tumours also differ between positions. On the bottom row,
it is possible to see that the blood sO2 of animal 4 is low, and in position
2, the ‘oxymap’ of the central slice of the tumour shows an atypically
large region of black pixels (41%).
Following the changes observed in the ‘oxymaps’ in Fig. 4, the
temporal changes in the ROI-averaged Hb, HbO2, HbT, sO2 and per-
centage of black pixels, were analysed, in order to investigate whether
re-positioning had an additive effect to the time the animal is under
anaesthesia in the temporal variability of the parameters analysed.
Fig. 5 shows the ROI-averaged percentage of black pixels for each
animal, in each of the three imaging positions, for the 3 central slices.
While there was some variations between animals and different posi-
tions, for the majority of the tumours the mean percentage of black
pixels (undetectable haemoglobin levels) was< 19%. Fig. 5 also shows
that re-positioning the animals resulted in significantly different
Fig. 3. sO2 distributions or ‘oxymaps’ of one tumour, at 5, 15, 30, 45, 60 and
75min after placing the animal in the tank. The ‘oxymaps’ are shown as
overlays on greyscale photoacoustic images, of the central slice of each tumour.
B: body; W: water. Yellow bar represents a 10mm size scale.
Table 1
Rate of change of ROI-averaged Hb, HbO2, HbT, sO2 and percentage of black pixels (%BP) signal during the short-term (75min) longitudinal study. The goodness of
fit, R2, indicates how much of the signal variability is time dependent and the p-value whether the signal change (slope of the linear model) is significantly different
from zero. The SSE reflects how similar the predicted values and measured data are, i.e. the closest SSE is to zero, the better the linear fit.
Animal Signal change, min−1 (95% CI) R2 p-value SSE
1 Hb HbO2
HbT
0.013 (0.012, 0.015)
0.016 (0.013, 0.018)
0.030 (0.027, 0.033)
0.968 0.932
0.976
< 0.001
<0.001
<0.001
0.037 0.117
0.142
sO2 0.0031 (0.0025, 0.0038) 0.895 < 0.001 0.007
%BP −0.278 (-0.392, -0.163) 0.679 < 0.001 255
2 Hb HbO2
HbT
0.013 (0.013, 0.014)
0.014 (0.013, 0.015)
0.027 (0.026, 0.028)
0.981 0.995
0.995
< 0.001
<0.001
<0.001
0.020 0.006
0.027
sO2 0.0027 (0.0023, 0.0032) 0.923 < 0.001 0.004
%BP −0.146 (-0.203, -0.0896) 0.704 < 0.001 63
3 Hb HbO2
HbT
0.0079 (0.0066, 0.0091)
0.0071 (0.0060, 0.0082)
0.015 (0.013, 0.017)
0.930 0.934
0.938
< 0.001
<0.001
<0.001
0.030 0.023
0.096
sO2 0.00025 (3.148e-05, 0.00047) 0.267 0.049 0.001
%BP -0.0284 (-0.037, -0.020) 0.799 < 0.001 1
4 Hb HbO2
HbT
0.0047 (0.0040, 0.0054)
0.0047 (0.0038, 0.0057)
0.0098 (0.0084, 0.011)
0.940 0.895
0.940
< 0.001
<0.001
<0.001
0.009 0.017
0.039
sO2 0.0029 (0.0022, 0.0035) 0.857 < 0.001 0.009
%BP −0.081 (-0.118, -0.043) 0.622 < 0.001 28
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measurements of haemoglobin content and blood sO2 levels. A trend for
an increase in ROI-averaged Hb, HbO2 and HbT was observed for most
animals over time, independent of the starting and ending angle of the
tumour relative to the transducer. ROI-averaged blood sO2 tended to
increase for animals 3 and 4 but remain more constant for animals 1
and 2. The ΔsO2 values tended to decrease over time, apart from animal
3.
The quantification of the changes in signal, both for the individual
haemoglobin components, blood sO2 and percentage of black pixels, is
shown in Table 2. As observed in the 75min imaging study, a trend for
an increase in Hb (> 0.0034 min−1), HbO2 (> 0.0050 min−1) and HbT
(> 0.0084 min−1) was observed over time. The p-values in Table 2
show that the slopes, i.e. changes in signal over time, for Hb, HbO2,
HbT and SO2, were not significantly different from zero.
No significant differences were found between the (temporal) signal
change calculated for the repositioning study and that obtained for the
longitudinal (75min) study, for ROI averaged Hb, HbO2, HbT and sO2,
apart for the HbT parameter for animal 2. Figs. S3–S5 show the long-
itudinal and re-positioning data for Hb, HbO2, HbT and SO2, for each
animal, plotted in the same figure, and the p-values showing the si-
milarity of the slopes, i.e. if pvalue<0.05 the temporal change in
signal was significantly different between the 75min and re-positioning
studies.
The slice- and intra-tumour CoVs for ROI-averaged Hb, HbO2, HbT
and sO2, are summarised in Table S2. The intra-tumour CoV measure-
ment of animal four, excluding position 2, where 46% of signal was lost,
is also shown. As was seen for the 75-minute study, the intra-tumour
CoVs for measurements acquired after re-positioning the animals was
higher for the haemoglobin components (Hb: 22.0±6.0%; HbO2:
40.0±11.0%; HbT: 28.1± 5.1%) than for blood sO2 (22.0 ± 21.2%
and 15.0 ± 11.3% with and without considering position 2 imaging
for animal 4, respectively). As for the ΔsO2 value, the intra-CoV was of
Fig. 4. A: Diagram for the re-positioning of the animal. Each
air-breathing imaging session started at approximately 5, 20
and 35min after placing the animal in the water tank of the
MSOT system. Air-breathing imaging takes approximately
2min. The air is then changed for 100%-O2, for 2min and the
same tumour region is re-imaged for approximately 2min
again, during O2-breathing. B: sO2 distributions or ‘oxymaps’
of 4 CALR tumours, positioned differently by remounting the
animals 3 times in the MSOT tank with the minimum time
interval between each imaging session. The ‘oxymaps’ are
shown as overlays on greyscale photoacoustic images, of the
central slice of each tumour. B: body; W: water. Yellow bar
represents a 10mm size scale.
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30.3 ± 11.3%. The slice-CoV was also lower (19.4 ± 18.4% including
animal 4, position 2 imaging) than the intra-tumour CoV.
The inter-CoV calculated was 25.8± 16.4% for the average Hb,
45.6±19.6% for the average HbO2, 30.6±15.6% for the average HbT
and 26.5±8.3% for the average sO2. Excluding that data point, the
inter-CoV calculated was of 20.4±16.4% for the average Hb,
33.2±6.4% for the average HbO2, 22.7± 6.8% for the average HbT
and 13.0± 13.2% for the average sO2. The inter-CoV for ΔsO2 value
was high (57.3 ± 18.6%).
3.2. Variation during tumour growth, 6 day study
For the long-term study, 10 CALR tumours were imaged. The ROI-
averaged Hb, HbO2, HbT, blood sO2 and ΔsO2 from 3 central slices per
tumour, measured during air-breathing and oxygen-breathing, for the
long term (6 day) variability study (total of 4 imaging sessions) are
shown in Figs. S7–S9.
From this data, the inter- and intra-tumour CoV for air-breathing
photoacoustic imaging, for 4 imaging sessions acquired over 6 days,
were calculated and are summarised in Tables S4 and S5. As was found
for the short term variability studies, the intra- and inter-tumour CoVs
for the sO2 parameter were lower (7.5±2.5% and 13.1± 3.2%, re-
spectively) than for the haemoglobin and ΔsO2 parameters (range
19.3±8.7%–39.7±5.6%).
Fig. 5. ROI-averaged percentage of black pixel, and Hb, HbO2, HbT, blood sO2 and ΔsO2 signals, for CALR tumours (n=4) imaged after being removed and re-
positioned in the tank three times, during air-breathing. Error bars represent the standard deviation over 3 adjacent central tumour slices, 1 mm apart. Solid lines
represent a linear regression fitted to the data.
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3.3. Tumour growth rate
Growth rates calculated for ten CALR tumours used in the long-
itudinal study are shown in Table 3. The individual fitted growth
curves, as well as the exponential-linear model fitting, are shown in
Fig. 6. The uncertainties (95% confidence intervals) are large and hence
no statistically significant differences were found between individual
tumour growth rates. The goodness of fit, R2, for the majority of the
tumours (N=8) was ≥ 0.88, suggesting good agreement between the
exponential-linear model and the data. Animals CALR-1 and CALR-8,
had abnormally low fits to the model. CALR-1 ulcerated, which can
affect the tumour growth (see Fig. 6). Fig. 6 shows stagnated tumour
growth (108 ± 18 mm3 to 123 ± 20mm3) between days 12–20 after
tumour implantation for CALR-8.
Table 3 shows that the time at which tumour growth changed from
exponential to linear varied from 2 to 10 days after tumour implant.
Based on these results and the growth curves shown in Fig. 6, all
photoacoustic imaging acquired for this study was performed during
the linear growth phase. In order to investigate whether these changes
were related to change in volume over time (ΔV), calculated using raw
caliper volume measurements, or linear rate of tumour growth (α1),
estimated using the exponential-linear model, the relationship between
these parameters and the percentage difference in sO2 between day 6
and day 1 was investigated and is shown in Fig. 7. A good negative
correlation between the percentage difference in sO2 and both ΔV and
α1, is seen, during oxygen-breathing, i.e. the larger the decrease in sO2
(oxygen-breathing), the faster the tumour was growing. Air-breathing
data is shown in Fig. S10.
4. Discussion
The main objective of this paper was to explore the variation of the
blood sO2, HbO2, Hb and HbT parameters in untreated subcutaneous
head and neck tumours measured with a tomographic photoacoustic
Table 2
Rate of change of ROI-averaged Hb, HbO2, HbT, blood sO2, ΔsO2 and percentage of black pixels (%BP) signal during the re-positioning study (air-breathing). The
goodness of fit, R2, indicates how much of the signal variability is time dependent and the p-value if the signal change (slope of the linear model) is significantly
different from zero. The SSE reflects how similar the predicted values and measured data are, i.e. the closest SSE is to zero, the better the linear fit.
Animal Signal change, min-1 (95% CI) R2 p-value SSE
1 HbT
%BP
Hb
0.030 (-0.077, 0.14)
-0.582 (-3.38, 2.21)
0.014 (-0.019, 0.047)
0923
0.875
0.966
0.179
0.231
0.120
0.031 22
0.003
HbO2 0.015 (-0.058, 0.089) 0.874 0.230 0.015
sO2 0.0051 (-0.034, 0.044) 0.738 0.340 0.004
ΔsO2 −0.0014 (-0.036, 0.033) 0.216 0.692 0.003
2 HbT
%BP
Hb
0.019 (-0.085, 0.12)
−0.162 (-1.79, 1.47)
0.0094 (-0.043, 0.062)
0.841
0.612
0.837
0.262
0.428
0.265
0.030 7
0.008
HbO2 0.0094 (-0.042, 0.060) 0.846 0.256 0.007
sO2 0.0018 (-0.0055, 0.0092) 0.911 0.188 <0.001
ΔsO2 −0.0013 (-0.0027, 9.34e-05) 0.993 0.057 5.79e-06
3 HbT
%BP
Hb
0.022 (-0.10, 0.15)
0.0071 (-0.490, 0.504)
0.012 (-0.079, 0.10)
0.829
0.031
0.742
0.271
0.887
0.339
0.043
0.688
0.023
HbO2 0.0096 (-0.025, 0.044) 0.927 0.174 0.003
sO2 0.00041 (-0.010, 0.011) 0.189 0.018 <0.001
ΔsO2 0.0013 (-0.0067, 0.0093) 0.804 0.291 1.86e-04
4 HbT %BP 0.0084 (-0.20, 0.22)
0.204 (-19.3, 19.7)
0.207
0.017
0.700
0.917
0.122 1062
Hb 0.0034 (-0.11, 0.11) 0.136 0.762 0.033
HbO2 0.0050 (-0.096, 0.11) 0.289 0.639 0.028
sO2 0.0031 (-0.090, 0.096) 0.153 0.155 0.024
ΔsO2 -0.00024 (-0.011, 0.011) 0.071 0.829 3.40e-04
Table 3
Exponential (α0) and linear (α1) growth rates, and time after implantation for transition between exponential and linear phase, τ, for 10 CALR tumours, including the
goodness of fit (R2) of the exponential-linear model to the growth curves.
Mouse α0
(day−1)
95%
confidence interval for α0
α1
(mm3.day−1)
95%
confidence interval for α1
τ (days
after
tumour implant)
Goodness
of fit (R2)
CALR-1 0.55 [0.24; 0.85] 23 [0.48; 45] 5 0.77
CALR-2 0.53 [0.41; 0.65] 46 [29; 63] 6 0.92
CALR-3 0.48 [0.28; 0.68] 11 [8; 14] 5 0.90
CALR-4 0.48 [0.36; 0.60] 10 [9; 12] 5 0.95
CALR-5 0.48 [0.36; 0.60] 48 [16; 79] 6 0.88
CALR-6 0.66 [0.52; 0.81] 55 [38; 72] 4 0.97
CALR-7 0.50 [0.43; 0.56] 26 [21; 32] 5 0.99
CALR-8 0.33 [0.26; 0.39] 49 [0; 110] 10 0.64
CALR-9 1.2 [0; 2.7] 10 [7; 12] 2 0.95
CALR-10 0.77 [0.22; 1.3] 30 [18; 42] 3 0.96
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system, with time, over short (minutes-hours) and long periods (several
days), and with position of the animals in the imaging cradle. From
these studies, it was possible to quantify the variability due to anaes-
thesia, tumour growth and re-positioning. This baseline information is
required for assessing the significance of any changes in these char-
acteristics that may be related to response to treatment, in future stu-
dies of the effects of radiotherapy and/or HIFU.
Initially, short-term variability of the PAI parameters was assessed.
The photoacoustic signal variability over 75min was measured to
investigate whether the injectable anaesthesia could affect hae-
moglobin and blood sO2 measured in tumours. Fig. 2 shows a de-
creasing trend in black pixels, regions where HbT is too low to be
measured, after the first 10min of imaging. Shah et al. [23] showed, by
co-registration of PAI (using this system) and microbubble contrast-
enhanced ultrasound images, that the black regions in tumours (in
mice) did not lack perfusion, although they typically exhibited lower
levels of perfusion and later microbubble arrival than other regions
within the tumour. The MSOT and the software available at the moment
Fig. 6. CALR tumour volume, as measured by calipers (blue circles). Error bars represent tumour volume error, as described by Eq. 2. The exponential-linear fitted
model is shown by the blue full line with 95% confidence intervals (dashed red lines).
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are still 1st generation and efforts are being made to improve the de-
tection of HbT in order to eliminate the occurrence of black pixels.
During the 75min in which in the percentage of black pixels tended
to decrease, an increase in Hb, HbO2 and HbT (Fig. 2 and Table 1) was
measured, resulting in increased blood sO2 for 3 out of 4 animals. These
results suggest peripheral vasodilation. The combination of medeto-
midine, fentanyl and midazolam used for this study has been shown to
cause a significant increase in blood pressure in rabbits, rats, and mice,
which could arise from an increase in vascular resistance or peripheral
vasoconstriction [33,37,38]. However, it is well-known that the cardi-
ovascular effects of the combination of these anaesthetic agents vary in
different species [39] and to the authors’ knowledge, there have been
no reports on its effect in female FOXnun1 mice. Furthermore, there is a
trend for decrease in sO2 and decrease in body temperature. Our results
suggest that these are not the cardiovascular effects we are measuring.
The increase in HbT and sO2 in our study can be due to a cardiovascular
effect of the anaesthetic agent combination, due to an influence of the
hydrodynamic pressure when the animal is enveloped in a plastic film
and submerged inside the water tank, or due to an influence of the
compression of the tumour due to the animal’s body weight, which
possibly stops blood outflow from the tumour. All these factors could
have contributed to the trend that was observed and further work is
necessary to understand its source. Indeed, a study of the effects of the
MSOT experimental setup on the animal’s tissue and blood gases would
be quite important, but it is not possible to perform with the current
hardware.
The trend for an increase in haemoglobin was observed during the
whole duration of imaging session, so the signal does not stabilise
during an acceptable period of anaesthesia for a small animal.
Therefore, this baseline change in signal needs to be considered in fu-
ture studies, as it is not possible to wait for long enough for a stable
signal to be seen before starting imaging the animal.
The inter- and intra-tumour CoVs (as shown in Table S1) were si-
milar in this study,> 16.0 ± 8.4% and>20.9 ± 3.1%, respectively,
for the parameters analysed: Hb, HbO2, HbT and sO2. This reflects a
high variation in the measured signal of each animal, probably due to
the increasing trend in haemoglobin and blood sO2 over time. Joseph
et al. (2017) [30] studied the repeatability and reproducibility of PAI
with the same system as that used here in the left kidney and spleen of
8–12 week old mice (n=7), acquiring images over a period of 90min,
under isoflurane anaesthesia. Interestingly, with this anaesthetic, the
authors found a steady increasing trend in HbT and blood sO2 over the
90min imaging acquisition time. The group reported that the intra-
organ CoVs for haemoglobin (Hb, HbO2 and HbT, measurements
averaged over a single ROI) for spleen was below 16.4 and for kidney
below 18.5, while for sO2 these values dropped to 3.9 and 3.4,
respectively. The CoVs measured in this paper during 75min of imaging
in subcutaneous tumours were higher than those reported in spleen and
kidney, although it is not possible to compare the uncertainties in the
measurements. In the experiment conducted by Joseph et al [30], the
organs (spleen and left kidney) were located deep within the animal’s
body, so there was likely to be minimal compression of their blood
supply due to mounting in the system, unlike the situation for sub-
cutaneous tumour, located superficially. This is in addition to the de-
ficient vascular supply that renders tumours prone to ‘cyclic’ hypoxia
[2], which can affect the measurements of haemoglobin and oxygen
saturation.
In the second study reported here, the effects of re-positioning the
animal three times during one imaging session were analysed. Fig. 4
shows that the shape of the tumour may vary considerably during re-
positioning of the animal, changing the size of the tumour-ROI used for
analysis. Subcutaneous tumours, besides being subject to compression
due to the animal’s body weight acting against buoyancy, as well as due
to hydrostatic pressure, can move relative to underlying anatomy as the
skin can be highly mobile. Therefore, during longitudinal studies it
would be important for the user to place the animal and tumour in the
same position relative to the MSOT mouse holder. From Fig. 4, it is
possible to observe differences in the ‘oxymaps’ depending on the po-
sition of the animal, which can result in differences in the distribution
and intensity of blue/red pixels. A radial gradient in blood sO2 was
observed for all animals (as well as in the 75min study, Fig. 3). This
might be due to lack of light fluence correction, ie, the MSOT system
does not take in consideration changes in light absorption with depth,
although efforts are being made to implement this correction [39]. In
mouse 4, position 2 resulted in an atypically high number of black
pixels (46%), with correspondingly uncharacteristically low levels of
Hb, HbT and sO2. However, this was observed in only one imaging scan,
for one animal out of twelve, so the likelihood of this type of artefact is
very low.
In order to investigate whether the differences in ‘oxymaps’ during
the re-positioning study also resulted in significant differences in ROI-
averaged photoacoustic imaging measurements (Hb, HbO2, HbT and
sO2) over time, the temporal changes in these measurements were
calculated. A trend for an increase in the haemoglobin components
amount was also observed, as in the 75-minute study. Animal 3 ex-
hibited no trend in levels of sO2 compared to the other two animals,
consistent with the observations of the sequential imaging for a period
of 75min. Table 2 shows that for this study, the p-values were> 0.05
so the slopes (change in signal) were not significantly different from
zero. This is likely to be due to the low (n=3 positions) number of
points, per animal.
From Figs. S3–S5, it is also possible to observe that there were no
Fig. 7. Correlation between rate of change in volume between day 1 and 6 of imaging, ΔV, or linear growth rate, α1, and the percentage difference in sO2 between
days 1 and 6 of imaging for 8 CALR tumours, for oxygen-breathing measurements.
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significant differences between the various positions, for the slopes
representing the variation over the 75min of the imaging study. The
imaging for animal 4, in position 2 that resulted in a large number of
black pixels, increased the inter- and intra-tumour CoV for the re-po-
sitioning study. However, the majority of the signal in this imaging scan
was lost, so it is not possible to know if this decrease is a result of
changes in the tumour or simply an artefact due to the signal loss.
The inter- and intra-tumour CoV for the CALR tumours due the re-
positioning of the animal (Table S2) were> 22.0 ± 21.2% and>
26.5 ± 8.3%, respectively, for all the parameters (Hb, HbO2, HbT and
sO2), and hence similar to those obtained for the study without re-po-
sitioning the animal (see Table S1), over a 75-minute period, apart from
animal 4. This also suggests that anaesthesia is the main experimental
factor that contributes for the temporal variability of the signal, as
found by Joseph et al. [30].
The intra- and inter-tumour CoVs for the 6 day imaging study
were> 19.3 ± 8.7% and>27.0 ± 4.1%, respectively, for the hae-
moglobin parameters (Hb, HbO2 and HbT). The sO2 parameter showed
a lower intra-tumour CoV (7.5 ± 2.5%) in the long term studies, in
comparison to Hb, HbO2 and HbT. Joseph et al. [30] also demonstrated,
by imaging the animals on 3 consecutive days, that while the sO2 was
constant over time in kidney (maintained between 0.8 and 0.7) and
spleen (maintained between 0.6 and 0.8), for HbT the variation was
larger (between 25–16 A.U and 9–13 A.U. for spleen and left kidney,
respectively). These studies suggest that variation in blood sO2 is ex-
pected to be lower than that for haemoglobin. Also, the intra-tumour
blood sO2 variability is lower for the long-term study, over 6 days,
compared to that obtained for the 75min (16.0 ± 8.4%) and re-
positioning (22.0 ± 21.2%) studies, once more showing that time
under anaesthesia per imaging session should be minimised. The ΔsO2
CoVs were high (> 30%) in both the 6-day and repositioning study,
hence we did not consider this parameter to be as reliable as in Joseph
et al. [30] study.
In order to assess whether there was any dependence of tumour
blood sO2 on growth, the growth rates of the 10 CALR tumours during
two different growth stages, were calculated using the exponential-
linear model. The goodness of fit showed a good correlation (R2>0.8)
between the model and 8 datasets. Of the two animals omitted from
analysis, one of the tumours became ulcerated, which is known to in-
troduce an error in tumour measurement [41] and the other animal
showed an unexpected delay in tumour growth. Fig. 7 shows a good
linear relationship between the linear growth rate and the variation in
sO2 (R2= 0.72, n=8), during oxygen-breathing. A negative linear
relationship was found between the rate of change in volume calculated
just for the 6 days of imaging and percentage change in sO2
(R2=0.67). Tumours that grew faster (n=5) during the linear phase
(α1 > 20mm.day−1) had a decrease in sO2 [range of −10% to
−56%] between days 1 and 6 of imaging, probably because they out-
grew their blood supply before new vasculature could be formed.
Slower growing tumours (n= 3) exhibited an increase or no change in
sO2 [+12% and -1%], possibly because angiogenesis was occurring at a
rate similar to the tumour growth rate. Interestingly, Tomaszewski et al.
[40] used oxygen enhanced (OE)-PAI, to visualise the spatiotemporal
heterogeneity of tumour vascular function in a poorly differentiated
and aggressive prostate tumour model, PC3. They showed that sO2
(while O2 breathing) and ΔsO2 also decreased with tumour growth,
from a 30mm3 volume to time of culling. The CALR model used for this
project has also been shown to develop rapidly and become hypoxic
[40]. This observation showed that tumours of the same cell-line, al-
though inoculated on the same day in the same-mouse strain, grow
differently and this inherent biological variability should be considered
for studies involving long term assessment of vasculature changes in
response to a therapy.
A limitation of this study is that it evaluated the baseline variations
in the photoacoustic signal for only one tumour type, a subcutaneous
head and neck tumour model. Other tumour types might show different
variation. For example, Tomaszewski et al. [36] showed that two
prostate tumour models, PC3 and LNCaP, exhibited different haemo-
dynamic behaviour, as assessed by PAI.
5. Conclusions
This paper documents the variation in haemoglobin (Hb, HbO2 and
HbT) and oxygen saturation over short (up to 75min) and long (6 days)
periods, and the variation with repositioning of the animal, in untreated
subcutaneous head and neck tumours in nude mice. Time under an-
aesthesia is the largest source of temporal variability in the photo-
acoustic signal. To perform inter- and intra-animal comparison in
longitudinal studies, for example when assessing the effects of treat-
ment, ideally the imaging should be started at a fixed time point after
anaesthesia and, if possible, sham-treated animals should be imaged at
the same time points as the treated animals.
Positioning of the animal was found to influence image quality in a
limited number of animals; when reconstruction artefacts or an un-
expected absence in PAI signal are observed during the preview of the
scan, the animal can be removed and re-positioned to obtain improved
PAI signal. With a carefully planned experimental protocol, photo-
acoustic imaging could be used for assessing changes in tumour hae-
moglobin and oxygenation in longitudinal studies, including those de-
signed to assess cancer therapies that may affect vasculature and,
consequently, tumour oxygenation.
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